For research use only — not for human or veterinary use

Back to compounds
Semaglutide 15mg

Peptides

Semaglutide

Research classification
Peptides
Lot documentation pending import

Variant / strength

Price

$73.50

Availability

Out of stock

SKU BNX-SEMA-15MG

1
View lot testing

For laboratory research use only. Not for human or veterinary use.

Lot & quality

Lot-specific analytical documentation

No verified lot documentation is published for this compound yet. Results, laboratories and purity values are never shown without a source record for the exact lot.

View available lot-specific analytical documentation

Enter lot number

Verification connects to the BioNex lot and COA records in a later phase — no results are returned yet

  1. 01

    Lot Number

  2. 02

    COA

  3. 03

    HPLC

  4. 04

    Mass Spectrometry

  5. 05

    Purity

  6. 06

    Laboratory

  7. 07

    Testing Date

  8. 08

    QR Verification

Research snapshot

Verified research records currently indexed by BioNex

BioNex research coverage · Extended Review in Progress
Publication records
118
Registered clinical trials
21
Human interventional
15
Human observational
3
Preclinical
2
Reviews
28
International records
1
Years indexed
20062026

Categories are listed separately and must not be added together: publication records and registered trial records are different record types, and a single study may appear in more than one category.

Compound profile

Research overview

Curated research content has not yet been imported for this compound. No generated summary is shown in its place.

Classification

Research areas

  • Metabolic Signaling

Targets

Mechanisms under investigation

  • GLP-1 receptor agonism

    Established target

    Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist. Receptor agonism is established in the peer-reviewed clinical literature and in the approved product labelling.

    Source

Evidence

Evidence breakdown

Direct compound evidence

117

Publication records indexed as describing this compound directly.

Related evidence

0

Parent-molecule or fragment literature. Counted separately and never added to direct evidence.

Human research

  • Human interventional15
  • Human observational3

Records describing research in human participants.

Preclinical research

  • Animal2

Animal and laboratory records. Not human evidence.

Review literature

  • Reviews28

Reviews summarise other work rather than reporting new results.

Registered clinical trials

  • Registered trial records21

Registration records a study, not a result. Trials are counted separately from publications.

Scientific identity

Compound identity

Canonical scientific name
Semaglutide
Molecular formula
C187H291N45O59
Molecular weight
4113.6 g/mol
CAS number
910463-68-2
PubChem CID
56843331
UNII
53AXN4NNHX
Research classification
Peptides

Indexed literature describes: Identity data describe semaglutide parent molecule as represented by PubChem CID 56843331.

These records describe the scientific entity reported in the literature. Lot-specific analytical documentation is available through BioNex Quality Verification when provided for the applicable lot.

Scientific data

Compound
Semaglutide
Molecular formula
C187H291N45O59
Molecular weight
4113.6 g/mol
CAS number
910463-68-2
Research classification
Peptides

Global research

Research records by jurisdiction

Jurisdictions appear only where an indexed record establishes them. Research recorded in one country never implies authorisation in another.

Loading United Kingdom records

Published research

Representative recent records

Verified records currently indexed by BioNex

Loading records

Regulatory

Regulatory records by jurisdiction

Regulatory records are held separately from research evidence. Authorisation or regulatory activity in one jurisdiction never implies the same status in another.

  • FDA safety communication on compounded and illegally marketed semaglutide products

    U.S. Food and Drug Administration (FDA) · FDA postmarket drug safety communication regarding compounded and illegally marketed semaglutide products. Not an approval action for BioNex material and not an efficacy judgement. · 2026-05-31

    Not an approval determination

    Primary source

Scientific identity records describe the entity reported in the literature. Lot-specific analytical documentation is available through BioNex Quality Verification when provided for the applicable lot.

BioNex Research Intelligence summarizes and organizes scientific literature for research and educational purposes. Inclusion of a publication, clinical trial, or regulatory record does not constitute endorsement, clinical guidance, or evidence of safety or efficacy for human use.